Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alli hits European stores

This article was originally published in The Tan Sheet

Executive Summary

Pharmacies across Europe now sell GlaxoSmithKline's non-prescription weight-loss drug alli (orlistat 60 mg), the firm says April 20. The European Commission, in its first centralized Rx-to-OTC switch process, approved the product for non-Rx sale to adults with a body mass index of 28 kg/m2 or more in all 27 EU member countries (1"The Tan Sheet" Jan. 26, 2009, In Brief)

You may also be interested in...

GSK's Launches, Global Expansion Drive Consumer Sales Ahead Of Market

Brand innovation, continued investment in marketing and global expansion help drive up GlaxoSmithKline's consumer health care sales significantly faster than overall market growth, the firm says

Alli first centralized switch

The European Union approves GlaxoSmithKline's weight-loss drug alli (orlistat 60 mg) for nonprescription sale in all 27 member states and Norway. The company says Jan. 21 it plans to launch alli - the first centralized EU switch - in the coming months. While all EU members agree to sell alli as nonprescription, each country chooses whether to make it available over the counter or behind the counter, the European Medicines Agency says (1"The Tan Sheet" Nov. 17, 2008, p. 6)

Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings

Pink Sheet reporters and editors consider the fallout from Brainstorm Cell Therapeutics Inc.’s negative US FDA advisory committee decision on its ALS drug, the impact of a government shutdown on the agency, and a study showing only a limited possibility for significant savings in the first round of Medicare price negotiations.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts